129.47

1.46% 1.86

After Hours: 129.72 0.25 +0.19%

Palvella Therapeutics Inc (PVLA)

Overview News Price History Discussions Forecast

Palvella Therapeutics Inc stock is traded at $129.47, with a volume of 212.30K. It is up +1.46% in the last 24 hours and up +4.87% over the past month. Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Previous Close:

$127.61

Open:

$130

24h Volume:

212.30K

Relative Volume:

0.69

Market Cap:

$1.85B

Revenue:

$1.30M

Net Income/Loss:

$-41.72M

P/E Ratio:

-34.92

EPS:

-3.7071

Net Cash Flow:

$-25.01M

1W Performance:

+2.79%

1M Performance:

+4.87%

6M Performance:

+70.92%

1Y Performance:

+442.62%

1-Day Range:

$123.91

$132.47

1-Week Range:

$117.79

$132.47

52-Week Range:

$20.20

$151.18

Palvella Therapeutics Inc Stock (PVLA) Company Profile

Name

Palvella Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

(484) 253-1461

Address

353 W. LANCASTER AVENUE, WAYNE

Employee

Twitter

Next Earnings Date

2026-05-07

Latest SEC Filings

PVLA's Discussions on Twitter

Compare PVLA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PVLA Palvella Therapeutics Inc	129.47	1.83B	1.30M	-41.72M	-25.01M	-3.7071
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-26	Initiated	Mizuho	Outperform
Dec-05-25	Initiated	BTIG Research	Buy
Dec-04-25	Initiated	Craig Hallum	Buy
Nov-19-25	Upgrade	Raymond James	Outperform → Strong Buy
Sep-09-25	Initiated	Oppenheimer	Outperform
Aug-06-25	Initiated	Raymond James	Outperform
Jul-21-25	Initiated	Truist	Buy
Apr-09-25	Initiated	Chardan Capital Markets	Buy
Mar-26-25	Initiated	Stifel	Buy
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Feb-20-25	Initiated	Canaccord Genuity	Buy
Feb-05-25	Initiated	TD Cowen	Buy
Dec-26-24	Initiated	H.C. Wainwright	Buy
Dec-18-24	Initiated	Cantor Fitzgerald	Overweight
Mar-13-20	Upgrade	Robert W. Baird	Neutral → Outperform
Jul-30-19	Downgrade	Robert W. Baird	Outperform → Neutral
May-14-19	Initiated	Robert W. Baird	Outperform
Mar-19-18	Initiated	Evercore ISI	Outperform
Mar-19-18	Initiated	Jefferies	Buy
Jan-16-18	Reiterated	H.C. Wainwright	Buy
May-30-17	Initiated	Rodman & Renshaw	Buy
Aug-05-16	Resumed	ROTH Capital	Buy
Aug-12-15	Initiated	JMP Securities	Mkt Outperform
Jul-27-15	Initiated	Oppenheimer	Outperform
Jul-22-15	Initiated	ROTH Capital	Buy

View All

Palvella Therapeutics Inc Stock (PVLA) Latest News

May 05, 2026

Palvella to Report Q1 Results, Host May 7 Conference Call - MyChesCo

May 05, 2026

May 04, 2026

Palvella doses first patients in angiokeratoma trial By Investing.com - Investing.com Australia

May 04, 2026

Palvella doses first patients in angiokeratoma trial - Investing.com UK

May 04, 2026

Palvella Therapeutics Announces First Patients Dosed In Phase 2 Lotu Trial Of Fast Track-Designated Qtorin™ Rapamycin For Clinically Significant Angiokeratomas - TradingView

May 04, 2026

No FDA-approved therapy exists; Palvella starts angiokeratoma study - Stock Titan

May 04, 2026

Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas - Yahoo Finance Singapore

May 04, 2026

May 02, 2026

Jennison Associates LLC Has $40.56 Million Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat

May 02, 2026

May 01, 2026

Palvella Therapeutics (PVLA) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

May 01, 2026

Apr 30, 2026

Palvella Thrives Ahead of Q1 Figures - Baystreet.ca

Apr 30, 2026

Palvella Therapeutics to Host First Quarter 2026 Financial - GlobeNewswire

Apr 30, 2026

Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026 - Sahm

Apr 30, 2026

Apr 29, 2026

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Apr 29, 2026

Apr 28, 2026

Palvella Therapeutics (NASDAQ:PVLA) Shares Gap UpWhat's Next? - MarketBeat

Apr 28, 2026

Apr 27, 2026

Palvella to Present QTORIN Study Data at ISSVA 2026 Conference - MyChesCo

Apr 27, 2026

Deltec Asset Management LLC Has $251,000 Stock Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat

Apr 27, 2026

Apr 26, 2026

Palvella Therapeutics (PVLA) Price Target Increased by 39.58% to 115.65 - MSN

Apr 26, 2026

Certain Common Stock of Palvella Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-APR-2026. - marketscreener.com

Apr 26, 2026

Apr 25, 2026

New Palvella Director Brings Rare Disease Insight To Low Valued Stock - Yahoo Finance

Apr 25, 2026

Apr 24, 2026

PVLA Stock Price, Quote & Chart | PALVELLA THERAPEUTICS INC (NASDAQ:PVLA) - ChartMill

Apr 24, 2026

Apr 22, 2026

PVLA (Palvella Therapeutics Inc.) posts wider than expected Q4 2025 loss, shares dip 0.69% in today’s trading.Attention Driven Stocks - Cổng thông tin điện tử tỉnh Lào Cai

Apr 22, 2026

Analysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO) and Palvella Therapeutics (PVLA) - The Globe and Mail

Apr 22, 2026

Apr 21, 2026

Palvella Therapeutics Appoints John D. Doux to Board - MyChesCo

Apr 21, 2026

Apr 20, 2026

Palvella to present Phase 3, Phase 2 study results at ISSVA By Investing.com - Investing.com Australia

Apr 20, 2026

Palvella Therapeutics (PVLA) Stock Approaches Resistance (Volatility Increases) 2026-04-20Community Breakout Alerts - Xã Thanh Hà

Apr 20, 2026

Palvella to present Phase 3, Phase 2 study results at ISSVA - Investing.com

Apr 20, 2026

Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026 - Yahoo Finance

Apr 20, 2026

Apr 16, 2026

Palvella reports 2025 results, advances QTORIN drug pipeline - MSN

Apr 16, 2026